In This Article:
ImmunityBio (NASDAQ:IBRX) Full Year 2024 Results
Key Financial Results
-
Revenue: US$14.7m (up by US$14.1m from FY 2023).
-
Net loss: US$413.6m (loss narrowed by 29% from FY 2023).
-
US$0.59 loss per share (improved from US$1.15 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ImmunityBio EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 31%. Earnings per share (EPS) exceeded analyst estimates by 26%.
Looking ahead, revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 11% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with ImmunityBio (including 3 which are significant).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.